COL22A1 expression identifies aggressive glioma and independently predicts survival through integrated multiomics and clinical validation
Across bulk, single‑cell, and spatial layers, COL22A1 integrates molecular, cellular, and microenvironmental hallmarks of glioma aggressiveness. Its tumour‑centric expression, peri‑necrotic localisation, and independent prognostic value support COL22A1 as a robust biomarker and a tractable candidate for imaging or therapeutic strategies in treatment‑refractory disease.
Authors
- Dueng‐Yuan Hueng (ORCID: https://orcid.org/0000-0001-7868-3161)
- Yao‐Feng Li (ORCID: https://orcid.org/0000-0001-9601-8149)
- Wei-Wen Hsu (ORCID: https://orcid.org/0000-0002-8554-1265)
- Wen-Shin Song
- Pei-Chi Chang
Institutions
- Tri-Service General Hospital (TW)
- National Taitung University (TW)
- National Defense University (TW)
- Cheng Hsin General Hospital (TW)
- National Defense Medical Center (TW)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-10-21
- DOI
- https://doi.org/10.1007/s12672-025-03723-5
- Citations
- 1
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.63